财经首页
|
新浪首页
|
新浪导航
财经首页
美股首页
滚动
评论
经济数据
美股列表
中国概念股
美股行情中心
美股自选
(ATNM)
公司资讯
finviz | 2022年04月11日 19:17
Actinium Pharmaceuticals Presents Preclinical Data at AACR Showing HER3 Targeted Radiotherapy Combined with the CD47 Immunotherapy Magrolimab Increases the Anti-tumor Effect
finviz | 2022年02月22日 20:00
Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors
finviz | 2022年01月05日 19:30
Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRP Immunotherapy
finviz | 2021年12月14日 20:00
Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
finviz | 2021年12月14日 19:45
Actinium Pharmaceuticals, Inc. Reports 2 Remissions and 67% ORR in Patients with a TP53 Mutation in the Phase 1 portion of the Actimab-A Venetoclax Combination Trial in Patients with Relapsed or Refractory AML at the 63rd ASH Annual Meeting
finviz | 2021年12月13日 19:30
Actinium Pharmaceuticals, Inc. Announces Greater Difference of Approximately 5x for Iomab-B vs Control Arm in the Number of Patients Potentially Evaluable for the Primary Endpoint of the Pivotal Phase 3 SIERRA Trial at the 63rd ASH Annual Meeting
finviz | 2021年12月08日 20:25
Actinium Pharmaceuticals, Inc. Announces Participation in Two Panel Discussions at the 3rd Targeted Radiopharmaceuticals Summit
finviz | 2021年11月12日 20:15
Actinium Presents First Ever Data with a CD47 Immunotherapy in Combination with a HER2-Directed Targeted Radiotherapy in Solid Tumors at the Society for Immunotherapy for Cancer (SITC) Conference
finviz | 2021年11月12日 20:00
Actinium Highlights Actimab-A Combined with CD47 Immunotherapy Results in Upregulation of Calreticulin Leading to Enhanced Phagocytosis in AML at the Society for Immunotherapy for Cancer (SITC) Conference
finviz | 2021年11月04日 21:05
Actinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy
finviz | 2021年11月04日 21:03
Actinium Announces Multiple Abstracts Highlighting Iomab-B and Actimab-A Accepted for Presentation at the 63rd Annual American Society of Hematology Annual Meeting
finviz | 2021年10月01日 21:00
Actinium Announces Two Abstracts Highlighting Combinations of CD47 Targeting Immunotherapy with Targeted Radiotherapies in Solid Tumors and Blood Cancers Accepted for Presentation at Society for Immunotherapy for Cancer (SITC) Conference
finviz | 2021年09月28日 20:00
Actinium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29th
finviz | 2021年09月27日 20:00
Actinium Announces Expansion of R&D Team and Facilities to Accelerate Research Programs Focused on Solid Tumors and Novel Combinations with Checkpoint Inhibitors and Radioconjugates
finviz | 2021年09月23日 21:00
Actinium Announces Multiple Senior Leadership Appointments Including Chief Business and Commercial Officer, New Chief Medical Officer and Vice President, Patent and Legal Counsel
finviz | 2021年09月20日 20:36
Actinium to Present at Four Upcoming Investor Conferences
首页
 
上页
下页